BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31569166)

  • 1. The Prognostic Role of Pretreatment Neutrophil to Lymphocyte Ratio (NLR) in Malignant Adrenal Lesions Treated With Stereotactic Body Radiation Therapy (SBRT).
    Mills MN; Reddy AV; Richardson L; Richardson KM; Kersh CR
    Am J Clin Oncol; 2019 Dec; 42(12):945-950. PubMed ID: 31569166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer: Prognostic Factors for Disease Control and Survival.
    Qiu H; Katz AW; Chowdhry AK; Usuki KY; Singh DP; Metcalfe S; Cheruvu P; Chen Y; Okunieff P; Milano MT
    Am J Clin Oncol; 2018 Jan; 41(1):53-58. PubMed ID: 26270442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.
    Xu B; Zhao X; Chen D; Zhao W; Wang X; Ding C; Yuan Z; Zhang H
    BMC Cancer; 2023 Jan; 23(1):73. PubMed ID: 36681809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer.
    Zhao X; Zhu X; Fei J; Ren H; Cao Y; Ju X; Yuan Z; Zhang H
    Radiat Oncol; 2018 Oct; 13(1):205. PubMed ID: 30348187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
    Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
    Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
    Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
    BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio.
    Turri-Zanoni M; Salzano G; Lambertoni A; Giovannardi M; Karligkiotis A; Battaglia P; Castelnuovo P
    Head Neck; 2017 Apr; 39(4):730-736. PubMed ID: 28032937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiation therapy for curative treatment of adrenal metastases.
    Rudra S; Malik R; Ranck MC; Farrey K; Golden DW; Hasselle MD; Weichselbaum RR; Salama JK
    Technol Cancer Res Treat; 2013 Jun; 12(3):217-24. PubMed ID: 23369155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients.
    Scorsetti M; Alongi F; Filippi AR; Pentimalli S; Navarria P; Clerici E; Castiglioni S; Tozzi A; Reggiori G; Mancosu P; Ricardi U
    Acta Oncol; 2012 May; 51(5):618-23. PubMed ID: 22263925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.
    Barney BM; Olivier KR; Macdonald OK; Fong de Los Santos LE; Miller RC; Haddock MG
    Am J Clin Oncol; 2012 Dec; 35(6):537-42. PubMed ID: 21659830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis.
    Franzese C; Nicosia L; Facondo G; Lo Faro L; Cuccia F; Vullo G; Osti MF; Alongi F; Scorsetti M
    Clin Exp Metastasis; 2021 Dec; 38(6):511-518. PubMed ID: 34651241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity.
    Chance WW; Nguyen QN; Mehran R; Welsh JW; Gomez DR; Balter P; Komaki R; Liao Z; Chang JY
    Pract Radiat Oncol; 2017; 7(3):e195-e203. PubMed ID: 27743801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
    Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
    Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT.
    Alagappan M; Pollom EL; von Eyben R; Kozak MM; Aggarwal S; Poultsides GA; Koong AC; Chang DT
    Am J Clin Oncol; 2018 Mar; 41(3):242-247. PubMed ID: 26757436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer.
    Chan JC; Chan DL; Diakos CI; Engel A; Pavlakis N; Gill A; Clarke SJ
    Ann Surg; 2017 Mar; 265(3):539-546. PubMed ID: 27070934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.